PROBLEM TO BE SOLVED: To provide a method of predicting and determining whether a patient has susceptibility or resistance to anti-CD20 antibody drugs such as rituximab.SOLUTION: The method of predicting and determining whether a patient has susceptibility or resistance to anti-CD20 antibody drugs such as rituximab includes the steps of: analyzing expression levels of one or more protein markers selected from CD20, CD19, CD59, CD81 and PD-L1 in CD19, CD22, or CD79b positive microvesicles derived from patient-derived cells or body fluids and predicting susceptibility of the patient to anti-CD20 antibody drug.SELECTED DRAWING: NoneCOPYRIGHT: (C)2018,JPO&INPIT【課題】患者がリツキシマブ等の抗CD20抗体医薬品に対して感受性又は抵抗性を有するか否か予測・判断するための手法を提供する。【解決手段】患者由来の細胞又は体液由来のCD19、CD22、又はCD79b陽性である微小胞における、CD20、CD19、CD59、CD81及びPD-L1より選択される一又は複数のタンパク質マーカーの発現量を解析し、該解析の結果に基づいて、抗CD20抗体医薬品に対する患者の感受性の有無を予測する工程を含む、抗CD20抗体医薬品に対する患者の感受性の有無の予測方法。【選択図】なし
